Navigation Links
Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
Date:3/31/2009

SAN DIEGO, INDIANAPOLIS and CAMBRIDGE, Mass., March 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from DURATION-2, the second in a series of studies designed to test the superiority of exenatide once weekly, an investigational diabetes therapy, as compared to other diabetes medications.

This 26-week clinical study compared exenatide once weekly to maximum doses of sitagliptin or pioglitazone, two commonly prescribed oral diabetes medications, in 491 patients with type 2 diabetes taking stable doses of metformin. After completing 26 weeks of treatment, evaluable patients randomized to exenatide once weekly experienced a statistically significant reduction in A1C, a measure of average blood sugar over three months, of 1.7 percentage points from baseline, compared to a reduction of 1.0 percentage point for sitagliptin and 1.4 percentage points for pioglitazone. This finding represents a statistically significant benefit of exenatide once weekly over both sitagliptin and pioglitazone.

Treatment with exenatide once weekly also produced statistically significant differences in weight, with weight loss of 6.2 pounds at 26 weeks, compared with a loss of 1.9 pounds for sitagliptin, and a weight gain of 7.4 pounds for pioglitazone.

"Recognizing the importance of A1C control, it has become clear that health care providers need comparative data to better understand the relative value of therapeutic options," said Richard Bergenstal, M.D., executive director of the International Diabetes Center. "A once-weekly
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
2. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
3. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
4. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
5. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
6. One Year Study of Exenatide Treatment Showed Improved Beta-Cell Function
7. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
8. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
9. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
10. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
11. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today ... undertake a Phase 1 transdermal,oxycodone clinical trial aimed ... management product. Phosphagenics has submitted all necessary ... be conducted at CMAX - an independent clinical ...
... Phase 2 clinical development, PRINCETON, N.J., Sept. ... in the discovery and development of novel,small molecule ... 2a,clinical study of PS433540, the company,s lead internal ... receptor antagonist,(DARA) that is being developed as a ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:8/30/2014)... CA (PRWEB) August 30, 2014 According ... upheld a decision that requires Takeda Pharmaceutical Co. and ... punitive damages for claims that the drugmakers concealed information ... diabetes medication Actos. The case, Allen v. Takeda Pharmaceuticals ... District Court, Western District of Louisiana (Lafayette).* , According ...
(Date:8/30/2014)... 2014 United Theological Seminary is pleased to ... the Master of Theological Studies (MTS). , ... designed for students who wish to pursue further academic study ... to serve the Church and community. Previously, students needed to ... can attend classes from any location where there is an ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 Daily Gossip ... that keeps anxiety and panic attacks under control with ... Away" program review describes this new method as ... control panic attacks and overcome general anxiety related disorders. ... successful is the fact that it can be accessed ...
(Date:8/30/2014)... RB SEO Services, a well-recognized internet marketing ... businesses. , RBSEO Services knows this very well that ... optimization service. So, the company has introduced this service, ... , On being asked about the service, a senior ... SEO service because many small businesses expressed their inability ...
(Date:8/30/2014)... 2014 Acne is a common problem millions of ... nothing more than a daily nuisance, for some, it can have ... acne can even lead to dramatic mood swings and depression. ... to clear up their skin. In some cases, that can make ... trial and error, those on a quest for clearer skin can ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:United Theological Seminary Announces First Fully Online Degree 2Health News:Panic Away Review Reveals New Natural Remedy for Anxiety Patients 2Health News:RBSEO Services Introduces Low Cost SEO Service for Small Businesses 2Health News:Acne Treatment Reviews Added to Popular Treatment Website 2
... May 8 Large rallies in,Northern and ... a three-day,statewide unfair labor practice strike by ... medical facilities that succeeded in raising public,awareness ... Inter-Con,Security., (Photo: http://www.newscom.com/cgi-bin/prnh/20080508/DC21718 ), ...
... (May 8, 2008, Toronto, ON) Women suffering with ... psychotherapy from a specially trained nurse over the phone, ... the availability of a psychologist or psychiatrist. , Dr. ... at the Lawrence S. Bloomberg Faculty of Nursing, University ...
... ROTTERDAM, Netherlands, May 8 LyondellBasell Industries,has ... (HACCP),certification of its management systems at its ... where MonoPropyleneGlycol USP/EP,(MPG-USP/EP) is produced., HACCP ... on preventing,food safety hazards. The comprehensive nature ...
... 8 Covance Inc. (NYSE:,CVD) today announced that it ... "We are very pleased to have Joe Scodari ... 34-year career as a key leader in the,pharmaceutical and ... driving growth in large, complex global healthcare businesses,",said Joe ...
... lead to new, genetically targeted therapies , , ... about the molecular mechanisms that cause cardiac arrhythmia ... death has been uncovered by Rhode Island Hospital ... to the development of new, genetically targeted therapies ...
... INETICO, Inc. and TPABenefits, Inc.,of San Antonio, ... interface,between the INETICO system and the TPABenefits Web ... Claims Management, Pre-Certification,and Wellness data source and allows ... Pre-Certifications and Case Notes on the,TPABenefits Web Portal., ...
Cached Medicine News:Health News:Three-Day Strike by Hundreds of Security Officers at Kaiser Hospitals Succeeds in Raising Red Flag About Unfair Labor Practices 2Health News:Three-Day Strike by Hundreds of Security Officers at Kaiser Hospitals Succeeds in Raising Red Flag About Unfair Labor Practices 3Health News:Raising the Bar on MonoPropyleneGlycol USP/EP 2Health News:Covance Elects Joseph C. Scodari to Company's Board of Directors 2Health News:Study Offers Clues to Link Between Arrhythmia, Sudden Death 2Health News:INETICO, Inc. Creates Data Interface with TPABenefits, Inc. Offering a Powerful Care and Claims Management Solution 2
... A biopsy with the MAMMOTOME® ... effective, minimally invasive procedure using ... management.,Using computer-generated images to locate ... accurately pinpoint and map the ...
... SEAMGUARD® Staple Line Reinforcement Material is ... postoperative pulmonary air leaks and as ... This inert, biocompatible, ePTFE material requires ... easy to load and fire and ...
... for the repair of abdominal hernias. It ... two distinct sides. One side of ... of sodium hyaluronate and carboxymethylcellulose (similar to ... side is bioresorbable, providing a temporary physical ...
... The Hernia Repair Company, we recognize that ... limited fibrous tissue in-growth between the prosthesis ... polypropylene mesh. Like all the products in ... produces a clinically proven, versatile repair.,The Reconix ...
Medicine Products: